Aim: To assess the impact, feasibility and acceptability of a person-centred, blended delivery, wellbeing and healthy lifestyle program for adults with RA.

Methods: We conducted a single-group study with six people recruited from hospital outpatients. The program was delivered by a multidisciplinary team at a university over 16 weeks. The program commenced with 6 weeks of resilience training (2 h/week) followed by 8 weeks of concurrent supervised exercise training (75 min planning session then 1 h/week), nutrition counselling (75 min planning session then 30 min/fortnight) and behaviour change counselling (1 h/fortnight). Group in-person delivery was used for resilience, exercise and behaviour change components. Individual teleconferencing was used for nutrition counselling. Pre- and post-assessment impact measures included self-reported indicators of wellbeing, quality of life, physical activity, sitting time and diet composition; and objective indicators of physical functioning and anthropometry. Feasibility was assessed from participant attendance and acceptability was assessed from participant feedback. Data were analysed using Paired T-tests, Wilcoxon signed-rank and McNemar's tests.

Results: There were significant (p < 0.05) improvements in sitting time, diet composition (total Mediterranean diet adherence score, sugar, monounsaturated fatty acids, olive oil) and physical function (neuromuscular strength, endurance, exercise capacity). There were improvement trends for wellbeing, quality of life, physical activity, other dietary intake (fish, legumes, unsaturated lipids) and body mass index. Attendance was 77%–86% across program components. Participant feedback was positive with suggestions for more in-person group content and online support.

Conclusions: This program had positive impact, good feasibility and high acceptability. Future recommendations include additional group sessions for exercise and nutrition education and online exercise training. A larger randomised controlled trial is justified to determine efficacy.